EUVIMEDEUVIMED entdecken
Crossref

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Tao Bi, Pan Liang, Yanan Zhou, Hong Wang, Rui Huang, Qin Sun, Hongping Shen, Sijin Yang, Wei Ren, Zengjin Liu iD

Journal of Medicinal Chemistry · 09.11.2023 · 66 (21) · 14843-14852

DOI: 10.1021/acs.jmedchem.3c01423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.10.2023. Verfasst von Tao Bi und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of the Affiliated Traditional Chinese Medicine Hospital of Sout…. Hauptthemen laut MEDLINE: Neoplasms, Prodrugs, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Sichuan Provincial Administration of Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein degradation mediated by the proteolysis-targeting chimera (PROTAC) has emerged as an efficient strategy to accurately control intracellular protein levels. However, the development of PROTACs is limited by their systemic toxicity. Herein, we report a bioorthogonally activatable prodrug (BT-PROTAC) strategy to accurately control the activity of PROTACs. As a proof of concept, we introduced the highly reactive trans-cyclooctene into PROTAC molecule MZ1, the structure-acitivity relationships of which were well characterized previously, to construct the bioorthogonally activatable prodrug BT-PROTAC. Compared with MZ1, BT-PROTAC is incapable of degradation of BRD4 protein. However, BT-PROTAC can be activated by highly active tetrazine compound BODIPY-TZ in vitro. Furthermore, we could selectively degrade BRD4 protein in tumor tissue enabled by tumor-targeted tetrazine compound IR808-TZ. This strategy may represent an alternative to existing strategies and may be widely applied in the design of BT-PROTAC targeting other proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProdrugsProteolysis Targeting ChimeraHumansCell Cycle ProteinsNeoplasm ProteinsNuclear ProteinsProteolysisTranscription FactorsBoron CompoundsHeterocyclic Compounds, 1-RingIndolesVinyl CompoundsBromine CompoundsBromodomain Containing Proteins

Substanzen

Cell Cycle ProteinsNeoplasm ProteinsNuclear ProteinsProdrugsProteolysis Targeting ChimeraTranscription FactorsBoron CompoundsHeterocyclic Compounds, 1-RingIndolesVinyl Compounds

Autor:innen und Institutionen

  • National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Chunhui Road, Luzhou 646000, China.
  • Institute of Integrated Chinese and Western Medicine Southwest Medical University, Chunhui Road, Luzhou 646000, China.

ORCID-Profile: Zengjin Liu

Förderung

  • China Postdoctoral Science Foundation
  • Sichuan Provincial Administration of Traditional Chinese Medicine
  • State Administration of Traditional Chinese Medicine of the People's Republic of China
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Bi, T., Liang, P., Zhou, Y., Wang, H., Huang, R., Sun, Q., Shen, H., Yang, S., Ren, W., & Liu, Z. (2023). Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation. Journal of Medicinal Chemistry, 66(21), 14843-14852. https://doi.org/10.1021/acs.jmedchem.3c01423

Vancouver

Bi T, Liang P, Zhou Y, Wang H, Huang R, Sun Q, et al. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation. Journal of Medicinal Chemistry. 2023;66(21):14843-14852. doi:10.1021/acs.jmedchem.3c01423

BibTeX
@article{Bi2023,
  author = {Bi, Tao and Liang, Pan and Zhou, Yanan and Wang, Hong and Huang, Rui and Sun, Qin and Shen, Hongping and Yang, Sijin and Ren, Wei and Liu, Zengjin},
  title = {Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {21},
  pages = {14843--14852},
  doi = {10.1021/acs.jmedchem.3c01423}
}
Kostenlos starten →